Dr Adam R Winstock
Clinical Senior Lecturer, Honorary Consultant Psychiatrist
MBBS, BSc, MSc, MRCP, MRCPsych, FAChAM, MD
Dr Adam Winstock is an Honorary Consultant Addictions Psychiatrist at Maudsley Hospital and Lewisham Drug and Alcohol Service. He is also a Clinical Senior Lecturer in Addictions for the National Addictions Centre at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and Programme Leader for the MSc in Clinical and Public Health Aspects of Addiction at King’s College London.
Dr Winstock studied medicine at the Middlesex Hospital, qualifying in 1991 having taken a year out to do a psychology degree.
His general physician training was completed in London and Bath, and he gained Membership of the Royal College of Physicians (MRCP) in 1994.
He trained as a psychiatrist at the Maudsley and became Member of the Royal College of Psychiatrists (MRCPsych) in 1997. He then spent four years as a Clinical Lecturer at the Institute of Psychiatry, obtaining his Masters (MSc) in 1999 and his Certificate of Completion of Specialist Training (CSST) in general adult psychiatry and addiction psychiatry in 2001.
He moved to Australia in 2002, taking up the roles of Clinical Director for the South West Sydney Area Health Service Drug and Alcohol Service and Senior Lecturer at the National Drug and Alcohol Research Centre (NDARC), University of New South Wales. He completed his Doctor of Medicine (MD) qualification in 2008.
During his years in Australia, Dr Winstock was an active researcher and teacher, and was involved with state and national advisory committees. He returned to the UK in 2009.
Current research interests include cannabis withdrawal and dependence, legal highs and mephedrone, dance drugs, consumer knowledge and understanding of drug treatment, health literacy, and opioid medication diversion.
He has been involved previously in research covering: epidemiology of dance drug use; legal highs; MDMA, GHB, mephedrone and ketamine, blood-borne virus testing and vaccination; patient and staff training and evaluation; cannabis and stimulant withdrawal and the misuse of opioid medications.